Treatment of advanced non-small cell lung cancer.
In the last decade the treatment of advanced-metastatic non-small cell lung cancer has substantially improved. If in the early 90s there was still concern about the real efficacy of chemotherapy over best suppotive care alone in the advanced setting, constant developments in clinical research have demonstrated the survival advantage of active anti-cancer drugs not only in the first-line setting, but, lately, even in patients with recurrent disease after failure of two previous chemotherapy lines. With the premises of high throughput technologies, translational research is aiming to characterize patients and tumors on a molecular basis. With pharmacogenomics it would then be possible to accurately predict patient outcome and tailor the treatment strategy according to the geno-phenotype of single patients.
De Petris
L
L
5th Pneumo-Oncology Unit, Deparment of Lung Diseases, S. Camillo-Forlanini Hospitals, Rome, Italy.
Crinò
L
L
Scagliotti
G V
GV
Gridelli
C
C
Galetta
D
D
Metro
G
G
Novello
S
S
Maione
P
P
Colucci
G
G
de Marinis
F
F
D000971:Antineoplastic Combined Chemotherapy Protocols; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008495:Medical Oncology; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009367:Neoplasm Staging; D010597:Pharmacogenetics; D017671:Platinum Compounds / Q000008:administration & dosage; D011379:Prognosis
D017671:Platinum Compounds